Preoperative serum HE4 combined with CA125 testing for predicting the risk of suboptimal cytoreduction in advanced epithelial ovarian cancer.

Zhou C, Wu Y, Wang J, Zheng F

Open source

DOI
10.3389/fonc.2026.1886007
Published
2026
Container
Frontiers in oncology
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fonc.2026.1886007,
  title = {Preoperative serum HE4 combined with CA125 testing for predicting the risk of suboptimal cytoreduction in advanced epithelial ovarian cancer.},
  author = {Zhou C and Wu Y and Wang J and Zheng F},
  year = {2026},
  journal = {Frontiers in oncology},
  doi = {10.3389/fonc.2026.1886007},
  url = {https://doi.org/10.3389/fonc.2026.1886007}
}

RIS

TY  - JOUR
TI  - Preoperative serum HE4 combined with CA125 testing for predicting the risk of suboptimal cytoreduction in advanced epithelial ovarian cancer.
AU  - Zhou C
AU  - Wu Y
AU  - Wang J
AU  - Zheng F
PY  - 2026
JO  - Frontiers in oncology
DO  - 10.3389/fonc.2026.1886007
UR  - https://doi.org/10.3389/fonc.2026.1886007
ER  - 

APA

C, Z., Y, W., J, W., & F, Z. (2026). Preoperative serum HE4 combined with CA125 testing for predicting the risk of suboptimal cytoreduction in advanced epithelial ovarian cancer.. Frontiers in oncology. https://doi.org/10.3389/fonc.2026.1886007

Source records